JNJ weekly analysis: holds firm above $197.78 MA-20 — RSI signals overbought conditions

Traders Union
All News
Financial News
Johnson & Johnson slips 0.36% this week

Highlights

Johnson & Johnson reported Q4 revenue of $24.6 billion, up 9.1% year-over-year, with full-year sales reaching $94.2 billion, driven by Innovative Medicine and MedTech strength.
The company advanced its MedTech portfolio via FDA submission for the OTTAVA robotic system and continued preparations for the DePuy Synthes spinoff amid recent acquisitions.
Johnson & Johnson remains focused on managing cost pressures from tariffs and ongoing legal liabilities as related lawsuits continue to progress.

Earnings-driven optimism as MedTech gains offset cost pressures this week

Johnson & Johnson reported robust fourth-quarter results with Q4 revenue of $24.6 billion, up 9.1% year-over-year, and full-year sales totaling $94.2 billion. Strong performance in the Innovative Medicine and MedTech segments, notably driven by Darzalex, supported these results. The company advanced its MedTech portfolio by completing an FDA submission for the OTTAVA robotic surgical system, while ongoing acquisitions and preparations for the spinoff of DePuy Synthes also featured in recent developments. The company continues to address cost pressures from tariffs and legal liabilities as lawsuits move forward.

Overbought signals emerge as bullish technicals dominate over the week

On the weekly chart, JNJ trades firmly above the MA-20, MA-50, and MA-200, confirming ongoing bullish momentum. The Ichimoku Kijun line at $192.16 acts as the first dynamic support, while immediate resistance is noted near the recent high and the round level at $220. Momentum indicators such as MACD and ADX remain in buy territory, but several oscillators, including the RSI (above 72) and CCI, highlight an overbought market. The stock stayed close to the weekly range high of $220.08, with mild volatility and buyer dominance as reflected by the positive BBP.

Narrow weekly range forecast as consolidation and breakout risk persist

For the coming week, JNJ is expected to trade between $213.40 and $220.00, reflecting a continuation of the current consolidation phase. The probability of maintaining or modestly extending gains is very high, exceeding 80%, with downside risk considered limited. Sideways movement within this corridor remains the baseline scenario, though a breakout above $220.00 could trigger a move to new highs. Conversely, a fall below $213.40 would point to short-term profit-taking and open a path toward support in the $211.00 area.

Jainam Mehta, market strategist, notes Johnson & Johnson continues to display robust macro and technical strength this week, supported by solid earnings and standout momentum above key moving averages. He sees the $213.40–$220.00 corridor as offering an attractive zone for patient accumulation, with the overbought signals justifying a tactical pause for new entrants. Mehta suggests that, while a breakout above $220.00 could trigger renewed upside, the prevailing consolidation phase may be interrupted only by a contrarian pullback. "I am watching for either a confirmed break over $220.00 to add exposure, or a retreat toward support as a possible re-entry—otherwise, it’s prudent to protect gains and let the consolidation play out."

Previously it was noted that Johnson & Johnson has narrowed its 'innovative medicine' priorities to oncology, immunology, and neuroscience, with oncology at the center of its strategy. The company recently raised its forward outlook, projecting growth to continue accelerating into the new year, signaling confidence in its new approach.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.